U.S. Buys 1.4 Million Doses of Regeneron’s COVID-19 Antibody Cocktail

Regeneron Pharmaceuticals and the U.S. government have struck a deal for a further 1.4 million doses of REGEN-COV (casirivimab/imdevimab), the company’s antibody cocktail for prevention and treatment of COVID-19, bringing the government’s purchased total to almost 3 million doses.

The N.Y.-based drugmaker will provide the 1,200-mg doses for $2,100 each, making the supply agreement worth an estimated $2.94 billion.

REGEN-COV is currently authorized to prevent and treat COVID-19 infection in people aged 12 years and older who have been exposed to the coronavirus and are at high risk of progressing to severe disease.